Molecular mechanisms of ischemic preconditioning and postconditioning as putative therapeutic targets to reduce tumor survival and malignancy

Medical Hypotheses

Volumn 81, Issue 6, 2013, Pages 1141-1145

  Muscari, Claudio ^a,b,d   Giordano, Emanuele ^b,c,d   Bonafè, Francesca ^a,b   Govoni, Marco ^d   Pasini, Alice ^c   Guarnieri, Carlo ^a,b,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b National Institute for Cardiovascular Research   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MONOCLONAL ANTIBODY; NANOPARTICLE; NEW DRUG; POLYGLACTIN; POLYMER;

ADAPTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; DRUG DELIVERY SYSTEM; DRUG SELECTIVITY; HEART PROTECTION; HYPOTHESIS; INTERMITTENT HYPOXIA; ISCHEMIA; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; REPERFUSION; REPERFUSION INJURY; TUMOR CELL;

ADAPTATION, PHYSIOLOGICAL; CELL HYPOXIA; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84888440467     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.10.022     Document Type: Article

References (67)

1. Cardenas-Navia L.I., Mace D., Richardson R.A., Wilson D.F., Shan S., Dewist M.W. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res 2008, 68:5812-5819.
2. Martinive P., Defresne F., Bouzin C., et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 2006, 66:11736-11744.
3. Toffoli S., Michiels C. Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J 2008, 275:2991-3002.
4. Philip B., Ito K., Moreno-Sanchez R., Ralph S.J. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 2013, 34:1609-1707.
5. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
6. Cabarcas S.M., Mathews L.A., Farrar W. The cancer stem cell niche-there goes the neighborhood?. Int J Cancer 2011, 129:2315-2327.
7. Kaplan R.N., Psalia B., Lyden D. Niche-to-niche migration of bone-marrow derived cells. Trends Mol Med 2007, 13:72-81.
8. Muscari C., Bonafè F., Fiumana E., et al. Comparison between stem cells harvested from wet and dry lipoaspirates. Connect Tissue Res 2013, 54:34-40.
9. Zhang Y., Daquinag A.C., Amaya-Manzanares F., Sirin O., Tseng C., Kolonin M.G. Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. Cancer Res 2012, 72:5198-5208.
10. Penna C., Perrelli M.G., Karam J.P., et al. Pharmacologically active microcarriers influence VEGF-A effects on mesenchymal stem cell survival. J Cell Mol Med 2013, 17:192-204.
11. Muscari C., Bonafè F., Martin-Suarez S., et al. Restored perfusion and reduced inflammation in the infarcted heart after grafting stem cells with a hyaluronan-based scaffold. J Cell Mol Med 2013, 17:518-530.
12. Fiumana E., Pasquinelli G., Foroni L., et al. Localization of mesenchymal stem cells grafted with a hyaluronan-based scaffold in the infarcted heart. J Surg Res 2013, 179:e21-9.
13. Toole B.P., Slomiany M.G. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 2008, 18:244-250.
14. Folkins C., Shaked Y., Man S., et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 2009, 69:7243-7251.
15. Bhaskara V.K., Mohanam I., Rao J.S., Mohanam S. Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. PLos One 2012, 7:e30905.
16. Holmquist L., Jogi A., Pahlman S. Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells. Int J Cancer 2005, 116:218-225.
17. Louie E., Nik S., Chen J.S., et al. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 2010, 12:R94.
18. Daneau G., Boidot R., Martinive P., Feron O. Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation on endothelial and tumor cells in cyclic hypoxia: effect on angiogenesis and metastases. Clin Cancer Res 2010, 16:410-419.
19. He K., Xu T., Xu Y., Ring A., Kahn M., Goldkorn A. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. Int J Cancer 2014, 134:43-54.
20. Freiberg R.A., Krieg A.J., Giacca A.J., Hammond E.M. Checking in on hypoxia/reoxygenation. Cell Cycle 2006, 5:1304-1307.
21. Minamino T. Cardioprotection from ischemia/reperfusion injury. Circ J 2012, 76:1074-1082.
22. Alchera E., Dal Ponte C., Imarisio C., Albano E., Carini R. Molecular mechanisms of liver preconditioning. World J Gastroenterol 2010, 16:6058-6067.
23. Wever K.E., Menting T.P., Rovers M., et al. Ischemic preconditioning in the animal kidney, a systematic review and meta-analysis. PLoS One 2012, 7:e32296.
24. Dewhirst M.W., Cao Y., Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008, 8:425-437.
25. Bruberg K.G., Benjaminsen I.C., Dorum L.M., Rofstag E.K. Fluctuation in tumor blood perfusion assessed by dynamic contrast-enhanced MRI. Magn Reson Med 2007, 58:473-481.
26. Pries A.R., Schonfeld D., Gaehgens P., Kiani M.F., Coklet G.R. Diameter variability and microvascular flow resistance. Am J Physiol 1997, 272:H2716-25.
27. Bernhardt W.M., Warnecke C., Willam C., Tanaka T., Wiesener M.S., Eckardt K.U. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol 2007, 435:221-245.
28. Hausenloy D.J., Yellon D.M. The second window of preconditioning (SWOP). Where are we now?. Cardiovasc Drugs Ther 2010, 24:235-254.
29. Muscari C., Bonafè F., Gamberini C., Giordano E., Lenaz G., Caldarera C.M. Ischemic preconditioning preserves proton leakage from mitochondrial membranes but not oxidative phosphorylation during heart reperfusion. Cell Biochem Funct 2006, 24:511-518.
30. Ardehali H. Role of the mitochondrial ATP-sensitive K+ channels in cardioprotection. Acta Biochim Pol 2004, 51:379-390.
31. Pan T.T., Feng Z.N., Lee S.W., Moore P.K., Bian J.S. Endogenous hydrogen sulfide contributes to the cardioprotection by metabolic inhibition preconditioning in the rat ventricular myocytes. J Mol Cell Cardiol 2006, 40:119-130.
32. + channels in the cardiac inner mitochondrial membrane. Science 2002, 298:1029-1033.
33. Zhao Z.Q., Corvera J.S., Halkos M.E., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003, 285:H579-88.
34. Zhao Z.Q. Postconditioning in reperfusion injury: a status report. Cardiovasc Drugs Ther 2010, 24:265-279.
35. Cescon M., Carini R., Grazi G., et al. Variable activation of phosphoinositide 3-kinase influences the response of liver grafts to ischemic preconditioning. J Hepatol 2009, 50:937-947.
36. Karlenius T.C., Shah F., Di Trapani G., Clarke F.M., Tonissen K.F. Cycling hypoxia up-regulates thioredoxin levels in human MDA-MB-231 breast cancer cells. Biochem Biophys Res Communs 2012, 419:350-355.
37. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013, 381:166-175.
38. Piper H.M., Meuter K., Schafer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 2003, 75:S644-48.
39. Baxter G.F., Marber M.S., Patel V.C., Yellon D.M. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. Circulation 1994, 90:2993-3000.
40. Kositprapa C., Ockaili R.A., Kukreja R.C. Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart. J Mol Cell Cardiol 2001, 33:1355-1362.
41. Baxter G.F., Goma F.M., Yellon D.M. Involvement of protein kinase C in the delayed cytoprotection following sublethal ischaemia in rabbit myocardium. Br J Pharmacol 1995, 115:222-224.
42. Imagawa J., Baxter G.F., Yellon D.M. Genistein, a tyrosine kinase inhibitor, blocks the "second window of protection" 48h after ischemic preconditioning in the rabbit. J Mol Cell Cardiol 1997, 29:1885-1893.
43. Kis A., Yellon D.M., Baxter G.F. Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol 2003, 35:1063-1071.
44. Xuan Y.T., Tang X.L., Banerjee S., et al. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 1999, 84:1095-1109.
45. Yamashita N., Nishida M., Hoshida S., et al. Induction of manganese superoxide dismutase in rat cardiac myocytes increases tolerance to hypoxia 24 hours after preconditioning. J Clin Invest 1994, 94:2193-2199.
46. Zhou J.J., Pei J.M., Wang G.Y., et al. Inducible HSP70 mediates delayed cardioprotection via U-50488H pretreatment in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2001, 281:H40-7.
47. Shinmura K., Bolli R., Liu S.Q., et al. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res 2002, 91:240-246.
48. Jancso G., Cserepes B., Gasz B., et al. Expression and protective role of heme oxygenase-1 in delayed myocardial preconditioning. Ann NY Acad Sci 2007, 1095:251-261.
49. Patel H.H., Hsu A.K., Gross G.J. COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat. Life Sci 2004, 75:129-140.
50. Takano H., Manchikalapudi S., Tang X.L., et al. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation 1998, 98:441-449.
51. Ockaili R., Emani V.R., Okubo S., Brown M., Krottapalli K., Kukreja R.C. Opening of mitochondrial KATP channel induces early and delayed cardioprotective effect: role of nitric oxide. Am J Physiol 1999, 277:H2425-34.
52. Chen M., Zhou J.J., Kam K.W., et al. Roles of KATP channels in delayed cardioprotection and intracellular Ca(2+) in the rat heart as revealed by kappa-opioid receptor stimulation with U50488H. Br J Pharmacol 2003, 140:750-758.
53. Rajesh K.G., Sasaguri S., Suzuki R., Xing Y., Maeda H. Ischemic preconditioning prevents reperfusion heart injury in cardiac hypertrophy by activation of mitochondrial KATP channels. Int J Cardiol 2004, 96:41-49.
54. Penna C., Rastaldo R., Mancardi D., et al. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol 2006, 101:180-189.
55. Hausenloy D.J., Maddock H.L., Baxter G.F., Yellon D.M. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovasc Res 2002, 55:534-543.
56. Yin C., Salloum F.N., Kukreja R.C. A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res 2009, 104:572-575.
57. Thierry B. Drug nanocarriers and functional nanoparticles: applications in cancer therapy. Curr Drug Deliv 2009, 6:391-403.
58. Kocbek P., Obermajer N., Cegnar M., Kos J., Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007, 120:18-26.
59. Wang L., Su W., Liu Z., et al. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 2012, 33:5107-5114.
60. Liu X.Q., Xiong M.H., Shu X.T., Tang R.Z., Wang J. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Mol Pharmaceutics 2012, 9:2863-2874.
61. Kanwar J.R., Roy K., Kanwar R.K. Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 2011, 46:459-477.
62. Shigdar S., Qiao L., Zhou S.F., et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 2013, 330:84-95.
63. Bagalkot V., Gao X. SiRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano 2011, 5:8131-8139.
64. Lou D., Wang B., Wang Y., Cao Y. Selective killing of cancer stem cells by a novel dual-targeting strategy. Med Hypotheses 2012, 79:430-432.
65. Deonarain M.P., Kousparou C.A., Epenetos A.A. Antibodies targeting cancer stem cells. A new paradigm in immunotherapy?. MAbs 2009, 1:12-25.
66. Harris J.M., Chess R.B. Effect of PEGylation on pharmaceutical. Nat Rev Drug Discov 2003, 2:214-221.
67. Costantinou A., Epenetos A.A., Hreczuc-Hirst D., Jain S., Deonarain M.P. Modulation of antibody pharmacokinetics by chemical polysialylation. Bioconjug Chem 2008, 19:643-650.